Please login to the form below
Venclyxto
This page shows the latest Venclyxto news and features for those working in and with pharma, biotech and healthcare.
Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021
At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease. ... of 14.7 months in the Venclyxto group compared to 9.6 months in the control group.
Latest news
-
EC approves Venclyxto-based combinations for newly diagnosed AML
Venclyxto/Venclexta is a targeted medicine designed to inhibit the B-cell lymphoma-2 (BCL-2) protein. ... By blocking the BCL-2 protein, Venclyxto helps to restore the process of apoptosis, resulting in cancer cell death.
-
AbbVie, Roche’s Venclyxto combo reduces risk of death in first-line AML
The safety profile of the treatment was found to be generally consistent with the known safety profiles of Venclyxto combined with azacitidine. ... In March, the European Commission approved Venclyxto in combination with Gazyvaro (obinutuzumab) as a
-
EU grants approval for Venclyxto/Gazyvaro combo in CLL
Chemotherapy-free option for previously-untreated patients. The European Commission has approved a combination of Roche’s Venclyxto and Gazyvaro as a chemotherapy-free therapy for previously-untreated chronic lymphocytic leukaemia ... Roche is
-
Venclexta plus Gazyva approval adds to non-chemo options in CLL
Venclexta (Venclyxto outside the US) is co-marketed by AbbVie and Roche and the combination with Gazyva in first line treatment of CLL could see its use expanded greatly. ... against Venclexta (Venclyxto).
-
Roche, AbbVie hit by clinical hold for Venclexta in myeloma
AbbVie and Roche certainly have high sales expectations for venetoclax, which is sold as Venclyxto outside the US, and have been steadily extending the drug’s uses as it heads towards
More from news
Approximately 7 fully matching, plus 6 partially matching documents found.
Subscribe to our email news alerts
- AstraZeneca and Daiichi Sankyo share positive results from phase 3 breast cancer study
- ICR and Merck renew strategic alliance for development of new cancer drugs
- DeepMind’s AI tool classifies effects of mutations in genetic diseases
- CDC awards over $23m to Johns Hopkins Center for Health Security project
- Looking to start activity on a currently unpromoted pharmaceutical brand?
- Considering a portfolio review?
No results were found
PMHub
Apex.co.uk Events and Exhibition Stands
Apex.co.uk is one of the UK’s leading exhibition stand and event agencies, specialising in healthcare. We understand your communication goals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
